These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 19002120)

  • 1. The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia.
    Roehrborn CG
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S19-26. PubMed ID: 19002120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study.
    Chung BH; Hong SJ; Cho JS; Seong DH
    BJU Int; 2006 Apr; 97(4):742-6. PubMed ID: 16536765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum prostate-specific antigen as a predictor of prostate volume in Korean men with lower urinary tract symptoms.
    Shim HB; Lee JK; Jung TY; Ku JH
    Prostate Cancer Prostatic Dis; 2007; 10(2):143-8. PubMed ID: 17199133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Correlation of serum prostate specific antigen, the volume and the intravesical prostatic protrusion for diagnosing bladder outlet obstruction in patients with benign prostate hyperplasia].
    Bantis A; Zissimopoulos A; Kalaytzis C; Giannakopoulos S; Sountoulides P; Agelonidou E; Voudalikakis C; Touloupidis S
    Hell J Nucl Med; 2007; 10(2):138-43. PubMed ID: 17684595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer.
    Canto EI; Singh H; Shariat SF; Lamb DJ; Mikolajczyk SD; Linton HJ; Rittenhouse HG; Kadmon D; Miles BJ; Slawin KM
    Urology; 2004 May; 63(5):905-10; discussion 910-1. PubMed ID: 15134977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
    Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
    Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
    Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Relationship between serum PSA and prostate volume in benign hyperplasia].
    Ojea Calvo A; Rodrigo AA; Verez Vivero MM; Rodríguez Iglesias B; Benavente Delgado J; Barros Rodríguez JM; Nogueira March JL
    Actas Urol Esp; 1994 Mar; 18(3):178-80. PubMed ID: 7518640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for disease progression in patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH): a systematic analysis of expert opinion.
    Lowe FC; Batista J; Berges R; Chartier-Kastler E; Conti G; Desgrandchamps F; Dreikorn K; O'Leary M; Perez M; Speakman M; Trachtenberg J; Tubaro A; Meesen B; Smets L; Stoevelaar H
    Prostate Cancer Prostatic Dis; 2005; 8(3):206-9. PubMed ID: 15953934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in relation to the patient's risk profile for progression.
    Trachtenberg J
    BJU Int; 2005 Jun; 95 Suppl 4():6-11. PubMed ID: 15871730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Definition of at-risk patients: dynamic variables.
    Emberton M
    BJU Int; 2006 Apr; 97 Suppl 2():12-5; discussion 21-2. PubMed ID: 16507047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Definition of at-risk patients: baseline variables.
    Roehrborn CG
    BJU Int; 2006 Apr; 97 Suppl 2():7-11; discussion 21-2. PubMed ID: 16507046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting.
    Mochtar CA; Kiemeney LA; Laguna MP; van Riemsdijk MM; Barnett GS; Debruyne FM; de la Rosette JJ
    Urology; 2005 Feb; 65(2):300-5. PubMed ID: 15708042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of prostate-specific antigen and prostate volume in Korean men with biopsy-proven benign prostatic hyperplasia.
    Lee SE; Chung JS; Han BK; Moon KH; Hwang SI; Lee HJ; Choe G; Hong SK
    Urology; 2008 Mar; 71(3):395-8. PubMed ID: 18342171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is screening for prostate cancer necessary in men with symptoms of benign prostatic hyperplasia?
    Hall MC; Roehrborn CG; McConnell JD
    Semin Urol Oncol; 1996 Aug; 14(3):122-33. PubMed ID: 8865473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Correlation of benign prostatic hyperplasia with hyperlipemia].
    Li PJ; Zhang XH; Guo LJ; Na YQ
    Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):387-9. PubMed ID: 15854349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of cell proliferation marker (TPS), natural killer (NK) activity and tumor load serotest (PSA) in untreated and treated prostatic tumors.
    Tarle M; Kovacić K; Kastelan M
    Anticancer Res; 1993; 13(1):215-8. PubMed ID: 7682800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validity of digital rectal examination and serum prostate specific antigen in the estimation of prostate volume in community-based men aged 50 to 78 years: the Krimpen Study.
    Bosch JL; Bohnen AM; Groeneveld FP
    Eur Urol; 2004 Dec; 46(6):753-9. PubMed ID: 15548443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of benign prostatic hyperplasia disease.
    Marks LS; Roehrborn CG; Andriole GL
    J Urol; 2006 Oct; 176(4 Pt 1):1299-306. PubMed ID: 16952616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical significance of prostatic-specific antigen levels in patients with benign prostatic hyperplasia complicated by low urinary tract syndrome].
    Zhu YJ; Ye M; Wang WM; Shen HB; Chen JH; Chen F
    Zhonghua Nan Ke Xue; 2006 Feb; 12(2):156-8. PubMed ID: 16519156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.